Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
18,211 total articles
Hanmi Financial Corporation, a NASDAQ-listed financial institution serving multi-ethnic communities through its subsidiary Hanmi Bank, announced its participation in the D.A. Davidson 16th Annual Western Bank Summit on August 11-12, 2026. The company's CEO and CFO will engage with institutional investors during virtual meetings. The event aims to p…
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company listed on Nasdaq, announced receipt of an additional A$5.1 million R&D tax incentive refund from the Australian Government. This completes over A$11.2 million received in 2026 as non-dilutive capital, enhancing the company's cash position and debt-free balance sheet to support adv…
Anavex Life Sciences Corp. filed its definitive proxy materials for the upcoming 2026 Annual Meeting, urging stockholders to vote for its six highly qualified, independent director nominees. The company highlights recent leadership changes to stabilize operations and advance its CNS-focused drug development programs, particularly the oral blarcames…
Neuronetics reported a 9.1% increase in total revenue for Q2 2026, driven by strong 16.8% growth in its Greenbrook interventional psychiatry clinics revenue. The company reduced its net loss to $3.4 million from $10.1 million year-over-year and achieved a positive adjusted EBITDA of $0.3 million compared to a loss previously. Operational improvemen…
Ryman Hospitality Properties announced a private placement of $700 million senior notes due 2035 to partially fund its $1.38 billion acquisition of JW Marriott Orlando Grande Lakes Resort and The Ritz-Carlton Orlando, Grande Lakes. The remainder of the purchase price is funded through a common stock offering and cash. The notes will be senior unsec…
Bicara Therapeutics reported Q2 2026 financials and strategic leadership updates. Ryan Cohlhepp will become CEO in January 2027, succeeding Claire Mazumdar who will transition to Vice Chair and Strategic Advisor. The company is progressing enrollment for the pivotal FORTIFI-HN01 trial of its lead drug, ficerafusp alfa, targeting HPV-negative head a…
Stardust Power Inc., a U.S.-based developer of battery-grade lithium carbonate refineries, appointed V. Ray Rivers to its Board of Directors. Rivers brings over 30 years of capital markets and financial services expertise, taking roles on the Audit and Compensation Committees. This strategic appointment aims to deepen the Board's financial expertis…
Eikon Therapeutics announced the selection of a 0.60 mg/m² dose for EIK1001 in the adaptive Phase 2/3 TeLuRide-006 trial for advanced melanoma, following a recommendation from an independent Data Monitoring Committee. EIK1001 is an investigational dual TLR7/8 agonist designed to stimulate innate and adaptive immunity, potentially enhancing response…
EVgo Inc. announced the opening of a new flagship EV fast charging station in Detroit in partnership with General Motors and Midwest retailer Meijer, part of a broader initiative to deploy over 100 flagship charging stalls nationwide by the end of 2026. These stations aim to enhance the EV charging experience with high-power, multi-stall sites loca…
ZenaTech, Inc., a Nasdaq-listed AI drone technology company, announced that its subsidiary ZenaDrone has begun flight testing custom-designed PCBs made in-house at its Taiwan subsidiary and integrated at its UAE facility. This advances their vertical integration strategy aimed at achieving NDAA-compliant Blue UAS certification, facilitating access …
Sagimet Biosciences reported its second quarter 2026 financial results, highlighting strategic focus on dermatology with plans to initiate a Phase 3 clinical trial of denifanstat for moderate to severe acne in the U.S. in the second half of 2026. The company also secured $175 million in equity financing in April 2026 and holds cash and marketable s…
TransUnion's latest research shows that 30% of Gen Z drivers have owned or driven uninsured vehicles in the past six months, significantly higher than other generations. This poses retention and underwriting challenges for insurers, emphasizing the need for better risk assessment tools and educational outreach to younger drivers.
Superior Group of Companies, Inc. announced the amendment and extension of its $200 million senior secured credit facilities with PNC Bank and lenders. The revolving credit facility and term loan remain at the same amounts with an added option for additional capacity, extending debt maturity from 2027 to 2031. This financial move enhances the compa…
Polar Power, Inc. has received new purchase orders for 15 additional Solar Hybrid Power Systems from a telecommunications company in the Solomon Islands. These orders build on successful deployments in 2024 and support expanding broadband infrastructure across remote islands. The company's DC-powered solar hybrid systems offer improved efficiency, …
Microchip Technology has introduced Revision 2.0 of its PolarFire FPGA Ethernet Sensor Bridge featuring a 60% smaller form factor, support for twice the number of cameras, USB-C power, and reduced pricing. Built on low-power PolarFire FPGA technology and integrating NVIDIA Holoscan Sensor Bridge technology, the board enables scalable, power-efficie…
Hub Group, Inc. has filed a notification of late filing for its Form 10-Q for Q2 2026 due to ongoing restatements of prior financial statements and delays in completing its Form 10-K for 2025. Despite operational challenges including higher fuel and rail costs, the company experienced balanced demand in intermodal and transportation solutions and g…
NeurAxis, a US-based medical technology company specializing in neuromodulation therapies, reported record financial results for Q2 2026, showing a 116% year-over-year revenue increase to $1.9 million. This growth was driven by a Category I CPT code assignment effective January 2026, which expanded payer coverage and increased full reimbursement sa…
Fennec Pharmaceuticals announced its Q2 2026 financial results showing a 78% year-over-year increase in net product sales to $17.1 million and a positive non-GAAP adjusted EBITDA of $2.8 million. The company highlighted record demand for its FDA-approved therapy PEDMARK®, designed to reduce cisplatin-induced ototoxicity in pediatric cancer patients…
AC Immune SA announced that the FDA granted Fast Track designation and approved its Investigational New Drug (IND) application for ACI-7104, an active immunotherapy targeting alpha-synuclein aggregates in early-stage Parkinson’s disease. Positive interim Phase 2 data demonstrated safety, tolerability, and immunogenicity, supporting further clinical…
Gain Therapeutics reported Q2 2026 financial results and provided updates on its Parkinson’s disease drug rexaceract, which received FDA IND clearance allowing Phase 2 trials to start in Q3 2026. Clinical data from the ongoing Phase 1b extension indicated durable benefits for patients, especially those with high baseline cerebrospinal fluid glucosy…
Prelude Therapeutics reported their Q2 2026 financial results highlighting significant progress in advancing their oncology pipeline. The company plans to initiate a Phase 1 clinical trial for PRT13722, a selective KAT6A degrader targeting HR+ breast cancer, in Q4 2026. Enrollment continues in the Phase 1 trial of PRT12396, a mutant-selective JAK2V…
Beamr Imaging Ltd. issued a CEO letter highlighting its expansion into the autonomous vehicle (AV) market by initiating its first structured engagements and integrating its AI-optimized video compression technology into AV platforms. The company continues to enhance its media and entertainment business, exemplified by large-scale deployments such a…
CalciMedica, a clinical-stage biopharmaceutical company, announced a $49 million private placement financing to advance its pulmonary hypertension (PH) program, including a Phase 1b proof-of-concept trial for Auxora in pulmonary arterial hypertension (PAH) and IND submission for oral CRAC inhibitor CM5480, both expected mid-2027. The FDA has aligne…
Aura Biosciences announced the full enrollment of its Phase 3 CoMpass trial with 108 patients, exceeding targets and on track for topline data in the second half of 2027, advancing development of belzupacap sarotalocan (bel-sar) for ocular cancers. The company is strategically concentrating resources on ocular oncology programs while deprioritizing…
Tango Therapeutics reported a strong Q2 2026 financial update highlighting encouraging Phase 1/2 clinical data for its cancer drug vopimetostat in combination with daraxonrasib for MTAP-deleted, RAS-mutant pancreatic cancer. The combination achieved a 92% objective response rate and 90% six-month progression-free survival, positioning it for late-s…
